Profund Advisors LLC reduced its holdings in shares of Halyard Health, Inc. (NYSE:HYH) by 30.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,160 shares of the medical instruments supplier’s stock after selling 3,148 shares during the quarter. Profund Advisors LLC’s holdings in Halyard Health were worth $281,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. BlackRock Inc. boosted its position in shares of Halyard Health by 6,362.1% during the 1st quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock worth $226,229,000 after acquiring an additional 5,847,442 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Halyard Health by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock worth $165,711,000 after acquiring an additional 196,367 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Halyard Health by 18.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,625,156 shares of the medical instruments supplier’s stock worth $99,992,000 after acquiring an additional 415,105 shares in the last quarter. State Street Corp boosted its position in shares of Halyard Health by 1.8% during the 1st quarter. State Street Corp now owns 1,583,269 shares of the medical instruments supplier’s stock worth $60,306,000 after acquiring an additional 28,718 shares in the last quarter. Finally, Paradice Investment Management LLC boosted its position in shares of Halyard Health by 5.7% during the 2nd quarter. Paradice Investment Management LLC now owns 1,532,981 shares of the medical instruments supplier’s stock worth $60,215,000 after acquiring an additional 83,000 shares in the last quarter. 91.02% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Profund Advisors LLC Has $281,000 Stake in Halyard Health, Inc. (HYH)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/11/profund-advisors-llc-has-281000-stake-in-halyard-health-inc-hyh.html.

HYH has been the subject of several analyst reports. Zacks Investment Research cut Halyard Health from a “buy” rating to a “sell” rating in a research report on Wednesday, October 4th. BidaskClub raised Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. TheStreet raised Halyard Health from a “c” rating to a “b” rating in a research report on Thursday, June 22nd. Stephens raised Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Finally, Deutsche Bank AG upped their target price on Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $42.25.

Shares of Halyard Health, Inc. (NYSE HYH) opened at 44.47 on Wednesday. The firm has a market capitalization of $2.08 billion, a PE ratio of 42.76 and a beta of 1.75. Halyard Health, Inc. has a 12 month low of $31.59 and a 12 month high of $46.63. The company has a 50 day moving average price of $45.27 and a 200-day moving average price of $40.42.

Halyard Health (NYSE:HYH) last posted its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.14. The business had revenue of $399.20 million during the quarter, compared to the consensus estimate of $399.16 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period last year, the firm earned $0.45 earnings per share. Equities research analysts expect that Halyard Health, Inc. will post $1.95 EPS for the current fiscal year.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.